The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease.

The efficacy and safety in canaglifrozin therapy for diabetes complicated by non-alcoholic fatty liver disease. - The efficacy of Canaglifrozin for NAFLD.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023044

Enrollment

Registered

2016-10-21

Start date

2016-11-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease type 2 diabetes mellitus

Interventions

canaglifrozin 100mg for 12 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c >6.0%, <10.0% Biopsy proven NAFLD (Kliner stage1-3) ALT>30U/L

Exclusion criteria

Exclusion criteria: administration of SGLT2 inhibitors type 1 diabetes platelet count<100000/microL eGFR<45m/min/1.73m2 diagnosed heart failure or malignancy

Design outcomes

Primary

Measure	Time frame
serum level of ALT at baseline and end of 12 weeks. The change of ALT between baseline and end of 12 weeks administration.	—

Secondary

Measure	Time frame
serum level of AST, GGT, ALP, HbA1c, fasting glucose, fasting insulin, c peptide, platelet count, uric acid, total cholesterol, triglyceride, HDL cholesterol, LDL cholesterol, hyaluronic acid, type 4 collagen 7s. waist circumference, NAFIC score, FIB-4 index, FM-fibro index, body composition, LSM, CAP, DEBQ, SF-8TM	—

Countries

Japan

Contacts

Public ContactYuya Seko

Kyoto prefetural University of Medicine Department of Gastroenterology and Hepatology

yuyaseko@koto.kpu-m.ac.jp0752515519

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026